Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Rybelsus is the first oral GLP-1 and is made by Novo Nordisk. This drug contains semaglutide, the active ingredient in ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

notes that the GLP-1 pill Rybelsus is already available, but only approved by the U.S. Food and Drug Administration (FDA) for diabetes treatment and not obesity. Orforglipron is aimed specifically ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from their spending on such drugs five years earlier, according to a research ...